Based in Gaithersburg, MD, Lentigen develops and commercializes therapeutics leveraging lentiviral vectors (LV) for numerous areas, including Stem Cell Therapies and Chimeric Antigen Receptor (CAR)- modified T cells for oncology indications. The new 5000 sq. ft. GMP manufacturing facility produces preclinical (non-GMP) and clinical (cGMP) lentiviral vectors in two independent suites. The suites are designed to meet US FDA and EU regulatory requirements for clinical grade manufacturing.
Miltenyi Biotec’s main GMP reagent and consumables manufacturing facility is located in Teterow, Germany. Here, we manufacture products which are qualified for use in cellular therapies. Operating under high quality standards (ISO 9001:2008 and ISO13485:2003), our plant produces e.g. cell culture media, GMP cytokines, freezing bags, high-end apheresis products and medical devices. A lentiviral vector manufacturing facility is under construction that will deliver customized research grade and GMP grade lentiviral vectors. The new facility will be operated with a manufacturing license according to §13 AMG. It increases the capacity of our lentiviral vector production and simplifies market access and distribution within Europe.
Miltenyi Biotec GmbH, Teterow
Phone: +49 3996 158-0
Fax: +49 3996 158-111
The headquarters of Miltenyi Biotec is located in Bergisch Gladbach, 20 kilometers east of Cologne. Our campus is home to our global centers for research and development, engineering, reagents and instrument manufacturing, business development, shipping, marketing, training, and technical support. It is easily accessible from the Cologne and Frankfurt International Airport as well as Cologne city center.
Miltenyi Biotec GmbH
51429 Bergisch Gladbach, Germany
Phone: +49 2204 8306-0
Fax: +49 2204 85197